The acute effects of flumazenil, a benzodiazepine (BZD) receptor antagonist in long-term BZD users were used as a possible test to detect physiological dependence. Thirty-four subjects (20 females, 14 males) aged 26-48 years (mean ± SD, 42.4 ± 8.5 years), all chronic users of low doses of diazepam (5-20 mg/day,14.2 ± 4.8 mg/day) for 5 to 28 years (10.5 ± 6 years), received a single 1-mg i.v. flumazenil dose or saline, infused slowly under double-blind conditions. Physiological dependence was suggested as all patients receiving flumazenil developed an anxiety reaction while the placebo group did not. Flumazenil triggered a qualitatively different reaction amounting to a panic attack during infusion in nine out of 15 patients. These patients had a diagnosis of panic disorder or a history of panic attacks. Caution should be exercised when giving flumazenil to panic patients who are taking BZDs as maintenance treatment.
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, (revised). American Psychiatric Association, Washington, DC
2.
Bernik M.A., Gorenstein C., Gentil V. (1991) Flumazenil precipitated withdrawal in chronic users of low doses of diazepam. J Psychopharmac5: 215-219
3.
Bernik M.A., Gorenstein C., Tavares S., Gentil F.V. (1989) Tolerância e dependência a benzodiazepinicos: a respeito de um caso. Rev Ass Med Bras35: 207-210
4.
Boisse N.R., Okamoto M. (1978) Physical dependence to barbital compared to pentobarbital IV Influence of elimination kinetics. J Pharmac Exp Ther204: 526-540
5.
Broagden R.N., Goa K.L. (1991) Flumazenil, a reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs42:1061-1089
6.
Clark D.M. (1986) A cognitive approach to panic. Behav Res Ther24: 461-470
7.
Cooper A.J. (1982) Benzodiazepines: towards more logical use. Scott Med J27: 297-304
8.
Cumin R., Bonetti E.P., Scherschlicht R., Haefely W.E. (1982) Use of the specific benzodiazepine antagonist Ro 15-1788 in studies of physiological dependence on benzodiazepines. Experientia38: 833-834
9.
Duka T., Ackenheil M., Noderer J., Doernicke A., Dorow R. (1986) Changes in noradrenaline plasma levels and behavioral responses induced by benzodiazepine agonists with the benzodiazepine antagonist Ro 15-1788. Psychopharmacology90: 351-357
10.
Gentil V., Tavares S., Gorenstein C., Mathias L., Gronich G., Singer J. (1990) Acute reversal of flunitrazepam effects by Ro 15-1788 and Ro 15-3505: inverse agonism, tolerance and rebound. Psychopharmacology100: 54-59
11.
Gloor P. (1972) Temporal lobe epilepsy: its possible contribution to the understanding of the functional significance of the amygdala and of its interaction with neocortical-temporal mechanisms. In Eleftheriou BE (ed.), The neurobiology of the amygdala. Plenum Press, New York
12.
Good R. ( 1940) Some observations of the psychological aspects of cardiazol therapy. J Ment Sci86: 491-501
13.
Graeff F.G. (1988) Animal models of aversion. In Simon P, Soubrié P, Widlocher D (eds), Selected models of anxiety, depression on psychosis - animal models of psychiatric disorder, Vol.1. Karger, Basle, pp 115-141
14.
Grant S.J., Gallaway M.P., Mayor R., Fenerty J.P., Finkelstein M., Roth R.H., Redmond ED (1985) Precipitated diazepam withdrawal elevates noradrenergic metabolism in primate brain. Eur J Pharmac107: 127-132
15.
Griffiths R.R., Evans S.M., Guarino J.J., Roache J.D., Furman W.R., Liebson I., Schwam E.M. (1993) Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: antagonism and precipitated withdrawal . J Pharmac Exp Ther265:1163-1174
16.
Hamilton M. (1959) The assessment of anxiety states by rating. Br J Med Psychol32: 50-55
17.
Hamilton M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiat23: 56-62
18.
Harrison-Read P.E., Tyrer P., Lawson C., Lack S., Fernandes C., File S.E. (1996) Flumazenil-precipitated panic and dysphoria in patients dependent on benzodiazepines: a possible aid to abstinence. J Psychopharmac10: 89-97
Hollister L.E., Müller-Oerlingerhausen B., Rickels K., Shader R.I. (1993) Clinical uses of the benzodiazepines. J Clin Psychopharmac13 (Suppl.): 1S-169S
21.
Klein D.F., Gorman J.M. (1987) A model of panic and agoraphobic development. Acta Psychiatr Scan76 (Suppl. 335) 87-95
22.
Little H.J., Nutt D.J., Taylor S.C. (1984) Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: proconvulsant properties and kindling. Br J Pharmac83: 951-958
23.
Little H.J., Nutt D.J., Taylor S.C. (1987) Bidirectional effects of chronic treatment with agonists and inverse agonists at the benzodiazepine receptor. Br Res Bull19: 371-378
24.
Loimber N., Hofman P., Chaudhry H.R. (1992) Nasal administration of naloxone for detection of opiate dependence. J Pschiat Res26: 39-43
25.
Lukas S.E., Griffiths R.R. (1982) Precipitated withdrawal with a benzodiazepine antagonist (Ro 15-1788) after 7 days of diazepam. Science217: 1161-1163
26.
Martin W.R., Sloan J.W., Wala E. ( 1990) Precipitated abstinence in orally dosed benzodiazepine-dependent dogs. J Pharmac Exp Ther255: 744-755
27.
McCloy R.F. (1995) Reversal of conscious sedation by flumazenil: current status and future prospects. Acta Anaesth Scand108 (Suppl.): 35-42
28.
Nutt DJ ( 1990) Pharmacological mechanisms of benzodiazepine withdrawal . J Psychiat Res24:105-110
29.
Nutt D.J., Glue P., Lawson C., Wilson S. (1990) Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder. Archs Gen Psychiat47: 917-925
30.
Nutt D.J., Smith C.F., Bennett R., Jackson H.C. (1992) Investigations on the set-point theory of benzodiazepine receptor function. Adv Biochem Psychopharmac47:419-428
31.
Peat M.A., Kopjak L. (1979) The screening and quantitation of diazepam, flurazepam, chlordiazepoxide, and their metabolites in blood and plasma by electron-capture gas chromatography and high pressure liquid chromatography. J Forens Sci24: 46-54
32.
Pecknold J.C., Swinson R.P., Kuch K., Lewis C.P. (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Archs Gen Psychiat45: 429-436
33.
Persson A., Pauli S., Hallding C., Stone-Elander S., Farde L., Sjögren I., Sedvall G. (1989) Saturation analysis of specific 11C Ro 15-1788 binding to the human neocortex using positron emission tomography . Hum Psychopharmac4: 21-31
34.
Petursson H., Lader M. (1984) Dependence on tranquilizers. Oxford University Press, Oxford
35.
Post R.M., Ketter TA, George M.S. (1993) Psychiatric syndromes and the limbic system. In Mesulam M (ed.), American Academy of Neurology Symposium: Limbic system in neurology and psychiatry. American Academy of Neurology, New York
36.
Rouiller M., ForsterA., Gemperle M. (1987) Evaluation de léfficacité et de la tolérance dün antagoniste des benzodiazépines (Ro 15-1788). Ann Fr Aesth Réanim6:1-6
37.
Savic I., Widén L., Stone-Elander S. (1991) Feasibility of reversing benzodiazepine tolerance with flumazenil. Lancet337:133-137
38.
Sloan J.W., Martin W.R., Wala E.P. (1991) A comparison of the physical dependence inducing properties of flunitrazepam and diazepam. Pharmacol Biochem Behav39: 395-405
39.
Spielberger CD, Gorsuch R.L., Lushene R.E. (1970) Manual for the state-trait anxiety inventory. Consulting Psychologists Press, Palo Alto, CA
40.
Spitzer R.L., Endicott J. (1979) Schedule for affective disorders and schizophrenia—life time version (SADS-L), 3rd edn. New York State Psychiatric Institute, New York
41.
Whitwam J.G., Amrein R. (1995) Pharmacology of flumazenil. Acta Anaesth Scand108 (Suppl.): 3-14
42.
Woods J.H., Katz J.L., Winger G. (1987) Abuse liability of benzodiazepines. Pharmac Ver39: 251-413
43.
Woods S.W., Charney D.S., Silver J.S., Krystal J.H., Heninger G.R. (1991) Behavioural, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiat Res36:115-127
